Reducing dysphagia with palliative 2D high-dose-rate brachytherapy improves survival in esophageal cancer.
HDR brachytherapy
dysphagia
esophageal cancer
palliation
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
18
09
2019
accepted:
19
11
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
24
1
2020
Statut:
ppublish
Résumé
The goal of this study was to assess the effectiveness of dysphagia relief and overall survival in patients with advanced esophageal cancer treated with palliative high-dose-rate (HDR) brachytherapy (BT) without computed tomography-based planning. Palliative 2D HDR-BT was used to treat 93 patients with advanced or incurable esophageal cancer in a regional cancer center from October 2010 to December 2016. Before the treatment patients presented the following grades of dysphagia: 0 - 0%, I - 57%, II - 33.3%, III - 6.5%, IV - 3.2%. The planned dose was 22.5 Gy in 3 fractions. The median age of patients was 65 years (45-88). Squamous cell carcinoma was diagnosed in 59.4%, adenocarcinoma in 22.6%, and other histological types of tumors in 6.7% of cases. The histopathological report was unknown in 11.3% of patients. The mean follow-up was 5.0 months (range 1-43). The median tumor length was 72.5 mm. Due to BT dysphagia was significantly decreased: grade 0 - 38.7%, I - 31.2%, II - 20.4%, IV - 1.1% ( 2D HDR-BT reduces dysphagia and prolongs survival in patients who respond to the treatment. It meets the assumption of palliative treatment for advanced esophageal cancer because of its simplicity and effectiveness.
Identifiants
pubmed: 31969911
doi: 10.5114/jcb.2019.91223
pii: 39401
pmc: PMC6964340
doi:
Types de publication
Journal Article
Langues
eng
Pagination
534-540Informations de copyright
Copyright © 2019 Termedia.
Références
Gut. 1982 Dec;23(12):1060-7
pubmed: 6184269
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):127-33
pubmed: 12007950
Med Phys. 2004 Mar;31(3):633-74
pubmed: 15070264
J Contemp Brachytherapy. 2009 Mar;1(1):25-32
pubmed: 27799950
Brachytherapy. 2004;3(4):191-5
pubmed: 15607150
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastrointest Endosc. 2005 Sep;62(3):333-40
pubmed: 16111947
Endoscopy. 2016 Oct;48(10):939-48
pubmed: 27626318
Lancet. 2004 Oct 23-29;364(9444):1497-504
pubmed: 15500894
Am J Gastroenterol. 2011 Sep;106(9):1612-20
pubmed: 21670770
Radiother Oncol. 2017 Mar;122(3):332-339
pubmed: 28104297
Clin Oncol (R Coll Radiol). 1995;7(2):102-5
pubmed: 7542470
Eur J Cancer. 2004 Aug;40(12):1862-71
pubmed: 15288288
PLoS One. 2012;7(7):e41352
pubmed: 22815994
Brachytherapy. 2004;3(2):87-94
pubmed: 15374540
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):447-53
pubmed: 9457834
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
Radiother Oncol. 2010 Dec;97(3):488-94
pubmed: 20950882
Dig Liver Dis. 2016 Oct;48(10):1233-6
pubmed: 27476465